BOSTON, March 07, 2017 -- Albireo Pharma, Inc. (Nasdaq:ALBO), an orphan pediatric liver disease company developing novel bile acid modulators, today announced that it will host a conference call and live audio webcast on Tuesday, March 14, 2017, at 8:30 a.m. ET to discuss its financial results for the year ended December 31, 2016, and provide a business update.
To access the live conference call by phone, dial 877-407-0792 (domestic) or 201-689-8263 (international) and provide the access code 13654743. The live audio webcast will be accessible from the Investors page of Albireo’s website, ir.albireopharma.com.
To ensure a timely connection to the call or webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will be available for replay on the Events & Presentations section of the Investors page of Albireo’s website for at least two weeks following the event.
About Albireo
Albireo is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo’s clinical pipeline includes two Phase 2 product candidates and one Phase 3 product candidate. Albireo was spun out from AstraZeneca in 2008.
Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.
Source: Albireo Pharma, Inc.
Investor Contact: Hans Vitzthum LifeSci Advisors, LLC. 212-915-2568 Media Contact: Heather Anderson 6 Degrees 980-938-0260 [email protected]


Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 



